Compare ZYME & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | ATHM |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2022 | 2013 |
| Metric | ZYME | ATHM |
|---|---|---|
| Price | $24.96 | $16.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | ★ $38.90 | $28.00 |
| AVG Volume (30 Days) | ★ 548.3K | 494.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 9.83% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | $4.77 |
| P/E Ratio | ★ N/A | $12.13 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.02 | $16.06 |
| 52 Week High | $29.75 | $29.92 |
| Indicator | ZYME | ATHM |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 29.83 |
| Support Level | $24.79 | N/A |
| Resistance Level | $27.54 | $19.50 |
| Average True Range (ATR) | 1.23 | 0.60 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 34.35 | 9.48 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.